NASDAQ:EVLO Evelo Biosciences (EVLO) Stock Price, News & Analysis → A Silent Invasion of America (From The Freeport Society) (Ad) Free EVLO Stock Alerts $0.06 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.06▼$0.0650-Day Range$0.00▼$0.0652-Week Range$0.00▼$13.93Volume29 shsAverage Volume1,502 shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Evelo Biosciences alerts: Email Address Ad Paradigm PressElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.See all the details you need here. About Evelo Biosciences Stock (NASDAQ:EVLO)Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More EVLO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVLO Stock News HeadlinesJune 13 at 6:38 AM | americanbankingnews.comEvelo Biosciences Sees Unusually Large Options Volume (NASDAQ:EVLO)February 22, 2024 | benzinga.comEvelo Biosciences Stock (OTC:EVLO), Short Interest ReportNovember 24, 2023 | msn.comEvelo Biosciences, a microbiome company launched by Flagship, shuts downNovember 22, 2023 | bizjournals.comFlagship-backed startup Evelo, behind failed eczema drug, to dissolveNovember 14, 2023 | finance.yahoo.comFMR LLC Reduces Stake in Evelo Biosciences IncNovember 10, 2023 | morningstar.comEvelo Biosciences Inc EVLONovember 2, 2023 | finance.yahoo.comQ3 2023 Horizon Technology Finance Corp Earnings CallNovember 2, 2023 | finance.yahoo.comHorizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call TranscriptNovember 1, 2023 | msn.comEvelo Biosciences (EVLO) Price Target Increased by 53.85% to 10.20October 19, 2023 | msn.comTD Cowen Downgrades Evelo Biosciences (EVLO)October 18, 2023 | finance.yahoo.comEvelo (EVLO) Drops 59% on Flunking Psoriasis Drug StudyOctober 17, 2023 | marketwatch.comEvelo Biosciences Shares Down 58% After Unfavorable EDP2939 ResultsOctober 17, 2023 | markets.businessinsider.comHold Rating on Evelo Biosciences amid Unfavorable Outcomes and Strategic Changes: An Analyst Recommendation ReportOctober 17, 2023 | seekingalpha.comEvelo drops as mid-stage trial for psoriasis drug failsOctober 17, 2023 | proactiveinvestors.comEvelo Biosciences shares tank 46% after trial failureOctober 17, 2023 | markets.businessinsider.comEvelo Biosciences: EDP2939-101 Study Fails To Meet Endpoint; To Explore Strategic AlternativesOctober 17, 2023 | msn.comWhy Is Psoriasis Company Evelo Biosciences Stock Plunging Today?October 17, 2023 | marketwatch.comEvelo Biosciences Reviewing Alternatives After Study Didn't Meet EndpointOctober 17, 2023 | marketwatch.comEvelo Biosciences to review options after Phase 2 trial of psoriasis treatment fails to meet main goalOctober 17, 2023 | finance.yahoo.comEvelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate PsoriasisAugust 18, 2023 | seekingalpha.comEvelo Biosciences down 39% as 13M share offering beginsAugust 14, 2023 | finanznachrichten.deEvelo Biosciences, Inc.: Evelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsAugust 14, 2023 | finance.yahoo.comEvelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsAugust 11, 2023 | finance.yahoo.comFMR LLC Acquires Significant Stake in Evelo Biosciences IncJuly 27, 2023 | msn.comMorgan Stanley Maintains Evelo Biosciences (EVLO) Equal-Weight RecommendationSee More Headlines Receive EVLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today6/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EVLO CUSIPN/A CIK1694665 Webwww.evelobio.com Phone(617) 577-0300FaxN/AEmployees66Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,530,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-189.58% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.92) per share Price / Book-0.07Miscellaneous Outstanding Shares18,980,000Free Float18,789,000Market Cap$1.14 million OptionableNo Data Beta1.75 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Craig R. Jalbert CIRA (Age 62)President, Secretary, Principal Executive, Financial and Accounting Officer & Director Dr. Chun Zhang Ph.D.Chief Technical Operations & Quality OfficerDr. Mark Bodmer Ph.D. (Age 66)Chief Scientific Officer and President of Research & Development Comp: $668.8kMs. Jessica CotroneVP & Head of CommunicationsMs. Leslie Wardwell-Scott Ph.D.VP and Head of Corporate Development & Strategic IntegrationDr. Andrea Itano Ph.D.Head of ResearchDr. Duncan McHale M.D. (Age 57)MBBS, Ph.D., Chief Medical Officer Comp: $661.97kMr. Douglas MaslinSenior Director & Immunology Clinical LeadMore ExecutivesKey CompetitorsBio-PathNASDAQ:BPTHArtelo BiosciencesNASDAQ:ARTLZyVersa TherapeuticsNASDAQ:ZVSAEvoke PharmaNASDAQ:EVOKAlzamend NeuroNASDAQ:ALZNView All CompetitorsInsidersMark BodmerSold 3,163 sharesTotal: $1,043.79 ($0.33/share)Marella ThorellSold 1,811 sharesTotal: $597.63 ($0.33/share)Simba GillSold 172 sharesTotal: $56.76 ($0.33/share)Simba GillSold 1,996 sharesTotal: $7,864.24 ($3.94/share)Mark BodmerSold 3,128 sharesTotal: $29,747.28 ($9.51/share)View All Insider Transactions EVLO Stock Analysis - Frequently Asked Questions Should I buy or sell Evelo Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EVLO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares. View EVLO analyst ratings or view top-rated stocks. How have EVLO shares performed in 2024? Evelo Biosciences' stock was trading at $0.0615 on January 1st, 2024. Since then, EVLO shares have decreased by 2.4% and is now trading at $0.06. View the best growth stocks for 2024 here. How were Evelo Biosciences' earnings last quarter? Evelo Biosciences, Inc. (NASDAQ:EVLO) posted its quarterly earnings results on Wednesday, October, 27th. The company reported ($12.60) earnings per share for the quarter, missing the consensus estimate of ($10.80) by $1.80. During the same period last year, the company earned ($9.00) earnings per share. When did Evelo Biosciences' stock split? Evelo Biosciences's stock reverse split on Friday, June 30th 2023. The 1-20 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Evelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX). When did Evelo Biosciences IPO? Evelo Biosciences (EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager. How do I buy shares of Evelo Biosciences? Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EVLO) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredDouble-Threat Biotech Could Deliver Triple-Digit GainsMost investors haven't heard of this under-the-radar biotech... But it could emerge as one of the premier A...Behind the Markets | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.